Relationship of Copeptin, a Surrogate Marker for Arginine Vasopressin, with Change in Total Kidney Volume and GFR Decline in Autosomal Dominant Polycystic Kidney Disease: Results from the CRISP Cohort

Overview

Journal Am J Kidney Dis

Specialty Nephrology

Date 2012 Oct 24

PMID 23089511

Citations 45

Authors

Wendy E Boertien

Esther Meijer

Jie Li

James E Bost

Joachim Struck

Michael F Flessner

Ron T Gansevoort

Vicente E Torres

Affiliations

Soon will be listed here.

Abstract

Background: Experimental studies indicate that arginine vasopressin (AVP) may have deleterious effects in the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). However, the significance of AVP in human ADPKD is unclear.

Study Design: Longitudinal observational study with 8.5 (IQR, 7.7-9.0) years' follow-up (CRISP [Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease]).

Setting & Participants: 241 patients with ADPKD with creatinine clearance >70 mL/min.

Predictor: Plasma copeptin concentration, a surrogate marker for AVP.

Outcomes: Change in measured glomerular filtration rate (mGFR, assessed by iothalamate clearance) and total kidney volume (measured by magnetic resonance imaging).

Measurements: Baseline copeptin level, plasma and urinary osmolality, and measurements of total kidney volume and mGFR during follow-up.

Results: In these patients (median age, 34 [IQR, 25-40] years; 38% men; median mGFR, 94 [IQR, 79-145] mL/min/1.73 m(2); median total kidney volume, 859 [IQR, 577-1,299] mL), median copeptin level was 2.9 (IQR, 1.8-5.1) pmol/L. Copeptin was not associated with plasma osmolality (P = 0.3), the physiologic stimulus for AVP release, but was associated significantly with change in total kidney volume during follow-up (P < 0.001). This association remained significant after adjusting for sex, age, cardiovascular risk factors, and diuretic use (P = 0.03). Copeptin level was associated borderline significantly with change in mGFR after adjusting for these variables (P = 0.09).

Limitations: No standardization of hydration status at time of copeptin measurement.

Conclusions: These data show that in ADPKD, copeptin level, as a marker for AVP, is not correlated with plasma osmolality. Most importantly, high copeptin levels are associated independently with disease progression in early ADPKD. This is in line with experimental studies that indicate a disease-promoting role for AVP.

Citing Articles

Fibroblast growth factor 23 but not copeptin is independently associated with kidney failure and mortality in patients with chronic kidney disease.

Michon-Colin A, Metzger M, Bankir L, Gauci C, Brunel M, Baron S Clin Kidney J. 2023; 16(12):2472-2481.

PMID: 38046034 PMC: 10689138. DOI: 10.1093/ckj/sfad149.

Predicting autosomal dominant polycystic kidney disease progression: review of promising Serum and urine biomarkers.

Soric Hosman I, Cvitkovic Roic A, Fistrek Prlic M, Vukovic Brinar I, Lamot L Front Pediatr. 2023; 11:1274435.

PMID: 38027263 PMC: 10667601. DOI: 10.3389/fped.2023.1274435.

Higher beta-hydroxybutyrate ketone levels associated with a slower kidney function decline in ADPKD.

Knol M, Bais T, Geertsema P, Connelly M, Bakker S, Gansevoort R Nephrol Dial Transplant. 2023; 39(5):838-847.

PMID: 37974030 PMC: 11181874. DOI: 10.1093/ndt/gfad239.

Copeptin in autosomal dominant polycystic kidney disease: real-world experiences from a large prospective cohort study.

Arjune S, Oehm S, Todorova P, Gansevoort R, Bakker S, Erger F Clin Kidney J. 2023; 16(11):2194-2204.

PMID: 37915893 PMC: 10616446. DOI: 10.1093/ckj/sfad118.

Identifying the main predictors of urine output in autosomal-dominant polycystic kidney disease (ADPKD) patients taking tolvaptan.

Borrego Utiel F, Morales Garcia A, Moyano A, Oporto F, Garcia E, de la Rosa R Int Urol Nephrol. 2023; 55(10):2629-2637.

PMID: 36952108 DOI: 10.1007/s11255-023-03555-8.

References

Grantham J . Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach. Kidney Int. 2003; 64(4):1157-62. DOI: 10.1046/j.1523-1755.2003.00242.x. View

King B, Torres V, Brummer M, Chapman A, Bae K, Glockner J . Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. Kidney Int. 2003; 64(6):2214-21. DOI: 10.1046/j.1523-1755.2003.00326.x. View

Torres V, Grantham J, Chapman A, Mrug M, Bae K, King Jr B . Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2010; 6(3):640-7. PMC: 3082424. DOI: 10.2215/CJN.03250410. View

Meijer E, Bakker S, Halbesma N, de Jong P, Struck J, Gansevoort R . Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int. 2009; 77(1):29-36. DOI: 10.1038/ki.2009.397. View

Belibi F, Reif G, Wallace D, Yamaguchi T, Olsen L, Li H . Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int. 2004; 66(3):964-73. DOI: 10.1111/j.1523-1755.2004.00843.x. View

Nagao S, Nishii K, Katsuyama M, Kurahashi H, Marunouchi T, Takahashi H . Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol. 2006; 17(8):2220-7. DOI: 10.1681/ASN.2006030251. View

Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B . Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int. 2005; 68(1):206-16. DOI: 10.1111/j.1523-1755.2005.00395.x. View

Szinnai G, Morgenthaler N, Berneis K, Struck J, Muller B, Keller U . Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab. 2007; 92(10):3973-8. DOI: 10.1210/jc.2007-0232. View

Ravine D, Gibson R, Walker R, Sheffield L, Kincaid-Smith P, Danks D . Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet. 1994; 343(8901):824-7. DOI: 10.1016/s0140-6736(94)92026-5. View

10.

Torres V, Meijer E, Bae K, Chapman A, Devuyst O, Gansevoort R . Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis. 2011; 57(5):692-9. DOI: 10.1053/j.ajkd.2010.11.029. View

11.

Fenske W, Stork S, Blechschmidt A, Maier S, Morgenthaler N, Allolio B . Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab. 2008; 94(1):123-9. DOI: 10.1210/jc.2008-1426. View

12.

Torres V, Wang X, Qian Q, Somlo S, Harris P, Gattone 2nd V . Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004; 10(4):363-4. DOI: 10.1038/nm1004. View

13.

Meijer E, Bakker S, de Jong P, Homan van der Heide J, van Son W, Struck J . Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation. 2009; 88(4):561-7. DOI: 10.1097/TP.0b013e3181b11ae4. View

14.

Meijer E, Rook M, Tent H, Navis G, van der Jagt E, de Jong P . Early renal abnormalities in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2010; 5(6):1091-8. PMC: 2879311. DOI: 10.2215/CJN.00360110. View

15.

Rule A, Torres V, Chapman A, Grantham J, Guay-Woodford L, Bae K . Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort. J Am Soc Nephrol. 2006; 17(3):854-62. DOI: 10.1681/ASN.2005070697. View

16.

Morgenthaler N, Struck J, Alonso C, Bergmann A . Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2005; 52(1):112-9. DOI: 10.1373/clinchem.2005.060038. View

17.

Wong H, Vivian L, Weiler G, Filler G . Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease. Am J Kidney Dis. 2004; 43(4):624-8. DOI: 10.1053/j.ajkd.2003.12.026. View

18.

Meijer E, Gansevoort R, de Jong P, van der Wal A, Leonhard W, de Krey S . Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. Nephrol Dial Transplant. 2011; 26(8):2445-53. DOI: 10.1093/ndt/gfr069. View

19.

Torres V, Harris P, Pirson Y . Autosomal dominant polycystic kidney disease. Lancet. 2007; 369(9569):1287-1301. DOI: 10.1016/S0140-6736(07)60601-1. View

20.

Meijer E, Bakker S, van der Jagt E, Navis G, de Jong P, Struck J . Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2010; 6(2):361-8. PMC: 3052227. DOI: 10.2215/CJN.04560510. View